😎 Summer Sale Exclusive - Up to 50% off AI-powered stock picks by InvestingProCLAIM SALE

Novavax tumbles 30% as waning COVID-19 vaccine demand hits outlook

Published 08/09/2022, 07:36 AM
Updated 08/09/2022, 06:40 PM
© Reuters. FILE PHOTO: Vials with a sticker reading, "COVID-19 / Coronavirus vaccine / Injection only" and a medical syringe are seen in front of a displayed Novavax logo in this illustration taken October 31, 2020. REUTERS/Dado Ruvic/Illustration/File Photo
PFE
-
NVAX
-
MRNA
-

(Reuters) -Shares of U.S. vaccine maker Novavax (NASDAQ:NVAX) fell about 30% on Tuesday after it cut its annual revenue forecast by half over falling demand for its COVID-19 shot from low- and middle-income nations.

Demand for its vaccine is also waning in the United States, where it was authorized for use among adults last month and was expected to be preferred by the skeptics of messenger RNA-based shots from Moderna (NASDAQ:MRNA) Inc and Pfizer Inc. (NYSE:PFE)

But only 7,381 Novavax vaccine doses have been administered so far in the country and Chief Executive Stanley Erck said that its late launch could have hampered demand.

The company now expects 2022 revenue between $2 billion and $2.3 billion, compared with its prior forecast of $4 billion to $5 billion when it was hoping to benefit from the demand for its shots as part of the COVAX vaccine sharing program.

Novavax shares fell 29.6% to close down at $40.28 a share.

"Timing continues to be our enemy," Novavax Chief Business Officer John Trizzino said in an interview.

He said the company does not expect to pick up significant market share of booster shots this fall as other vaccine makers roll out new shots designed to target newer COVID-19 variants.

Still, he said that developing its own updated version of the vaccine will help as the company gears up to compete next year.

"All of the obstacles that have been in our way in 2022 will not be there in '23," he said.

© Reuters. FILE PHOTO: Vials with a sticker reading,

Analysts still expect the company to capture a small but meaningful share of a fast-developing market for COVID-19 re-vaccinations.

It could still be a viable COVID vaccine player in the future $5-10 billion market as it has shown a comparable or better clinical profile versus mRNA vaccines, Jefferies analyst Roger Song said in a note.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.